Entity

Time filter

Source Type

Rochester, MN, United States

Varughese A.M.,University of Cincinnati | Rampersad S.E.,University of Washington | Whitney G.M.,Vanderbilt University | Flick R.P.,Mayo Clinic Childrens Center | Anton B.,Johns Hopkins University
Anesthesia and Analgesia | Year: 2013

Health care quality and value are leading issues in medicine today for patients, health care professionals, and policy makers. Outcome, safety, and service - the components of quality - have been used to define value when placed in the context of cost. Health care organizations and professionals are faced with the challenge of improving quality while reducing health care related costs to improve value. Measurement of quality is essential for assessing what is effective and what is not when working toward improving quality and value. However, there are few tools currently for assessing quality of care, and clinicians often lack the resources and skills required to conduct quality improvement work. In this article, we provide a brief review of quality improvement as a discipline and describe these efforts within pediatric anesthesiology. Copyright © 2013 International Anesthesia Research Society. Source


Baruth J.M.,Mayo Medical School | Wall C.A.,Mayo Medical School | Patterson M.C.,Mayo Clinic Childrens Center | Port J.D.,Mayo Medical School
Autism Research | Year: 2013

Proton magnetic resonance spectroscopy (1H-MRS) is a safe, noninvasive way of quantifying in vivo biochemical and metabolite concentration levels in individuals with Autism Spectrum Disorders (ASD). Findings to date suggest ASD is associated with widespread reduction in N-acetylaspartate (NAA), creatine plus phosphocreatine (Cr), choline-containing compounds (Cho), myo-inositol (mI), and glutamate plus glutamine plus gamma-Aminobutyric Acid (Glx); however, variable findings, and even substantial increases, are not uncommon depending on the study and/or region-of-interest. Widespread reduction of NAA, Cr, Cho, mI, and Glx in ASD likely reflects impaired neuronal function and/or metabolism related to abnormal neurodevelopmental processes. Future studies should attempt to relate 1H-MRS findings to histological findings and control for variability in subject age and functioning level; this would assist in evaluating the relationship between 1H-MRS metabolic levels and neuronal and glial cell densities, as well as neurodevelopmental process associated with ASD. Furthermore, more longitudinal 1H-MRS studies are needed in both control and ASD subjects to attempt to standardize metabolite levels across different developmental periods in well-defined endophenotypes. This will provide for a standard rubric for which metabolic aberrations (as well as treatment responses) can be measured. With higher magnetic field strengths and spectral-editing techniques capable of quantifying less-concentrated metabolites, 1H-MRS will continue to be an important tool in ASD research. Autism Res 2013, 6: 119-133. © 2013 International Society for Autism Research, Wiley Periodicals, Inc. Source


Isaya G.,Mayo Clinic Childrens Center
Frontiers in Pharmacology | Year: 2014

Growing evidence supports a role for mitochondrial iron metabolism in the pathophysiology of neurodegenerative disorders such as Friedreich ataxia (FRDA) and Parkinson disease (PD) as well as in the motor and cognitive decline associated with the aging process. Iron-sulfur enzyme deficits and regional iron accumulation have been observed in each of these conditions. In spite of significant etiological, clinical and pathological differences that exist between FRDA and PD, it is possible that defects in mitochondrial iron-sulfur clusters (ISCs) biogenesis represent a common underlying mechanism leading to abnormal intracellular iron distribution with mitochondrial iron accumulation, oxidative phosphorylation deficits and oxidative stress in susceptible cells and specific regions of the nervous system. Moreover, a similar mechanism may contribute to the age-dependent iron accumulation that occurs in certain brain regions such as the globus pallidus and the substantia nigra. Targeting chelatable iron and reactive oxygen species appear as possible therapeutic options for FRDA and PD, and possibly other age-related neurodegenerative conditions. However, new technology to interrogate ISC synthesis in humans is needed to (i) assess how defects in this pathway contribute to the natural history of neurodegenerative disorders and (ii) develop treatments to correct those defects early in the disease process, before they cause irreversible neuronal cell damage. © 2014 Isaya. Source


Bosenberg A.,University of Washington | Flick R.P.,Mayo Clinic Childrens Center
Clinics in Perinatology | Year: 2013

Optimal pain management can significantly impact the surgical outcome and length of stay in the neonatal intensive care unit (NICU). Regional anesthesia is an effective alternative that can be used in both term and preterm neonates. A variety of neuraxial and peripheral nerve blocks have been used for specific surgical and NICU procedures. Ultrasound guidance has increased the feasibility of using these techniques in neonates. Education and training staff in the use of continuous epidural infusions are important prerequisites for successful implementation of regional anesthesia in NICU management protocols. © 2013 Elsevier Inc. Source


Davidson A.,Royal Melbourne Hospital | Flick R.P.,Mayo Clinic Childrens Center
Clinics in Perinatology | Year: 2013

Laboratory studies have shown that general anesthetics may cause accelerated apoptosis and other adverse morphologic changes in neurons of the developing brain. The mechanism may be related to the neuronal quiescence or inactivity associated with anesthetic exposure. Few data exist on how brief anesthetic exposure may affect neurodevelopment in the newborn. Good evidence however shows that untreated pain and stress have an adverse effect on neurodevelopment, and therefore, at this stage, providing effective analgesia, sedation, and anesthesia would seem to be more important than concern over neurotoxicity. © 2013 Elsevier Inc. Source

Discover hidden collaborations